Impact of bone disease and pain in thalassemia

Hematology. American Society of Hematology. Education Program - Tập 2017 Số 1 - Trang 272-277 - 2017
Antonio Piga1
1Department of Clinical and Biological Sciences, University of Torino, Torino, Italy

Tóm tắt

AbstractConventional treatment of thalassemia, namely regular blood transfusion and iron chelation, improves perspectives and quality of life; however, successful treatment leads to more time in which long-term complications such as bone disease can develop. Thalassemia bone disease (TBD) is unique: all aspects, from bone anatomy and bone quality to mineral density, may be affected, with important morbidity including osteoporosis, fractures, spinal deformities, nerve compression, and pain. Clinical presentations include growth impairment, rickets-like features, back pain, spinal deformities, any sign of nerve compression, severe osteoporosis, and fragility fractures. Age, history, physical examination, and diagnostic tests support orientation on risk factors. These include bone marrow expansion, toxicity from iron overload and iron chelation, endocrine dysfunctions (hypogonadism, hypohyperparathyroidism, hypothyroidism, growth hormone deficiency, diabetes), and vitamin (D, C, K) and zinc deficiencies. Several of these may coexist in an individual for a long time and at different degrees, making clarification of the relative contribution and selection of the best therapeutic options a challenge. Milestones for prevention of TBD are early and full inhibition of bone marrow hyperplasia and iron toxicity. Empowering patients’ positive resources is key for achieving long-term healthy habits with regard to diet, physical activity, sunlight exposure, and lifestyle. Pain, related or unrelated to bone disease, is frequent in thalassemia. The most important targets for the hematologist include having an expert orientation on disease-related causes of pain, driving differential diagnosis, providing effective pain relief and, where feasible, removing the cause.

Từ khóa


Tài liệu tham khảo

Steer, 2017, J Bone Miner Res

Baldini, 2017, Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables, Ann Hematol, 96, 995, 10.1007/s00277-017-2959-0

Baldini, 2014, Bone disease in adult patients with β-thalassaemia major: a case-control study, Intern Emerg Med, 9, 59, 10.1007/s11739-011-0745-x

Tyler, 2006, The radiological appearances of thalassaemia, Clin Radiol, 61, 40, 10.1016/j.crad.2005.07.006

Xu, 2017, The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss, Bone, 94, 152, 10.1016/j.bone.2016.09.023

Jeney, 2017, Clinical impact and cellular mechanisms of iron overload-associated bone loss, Front Pharmacol, 8, 77, 10.3389/fphar.2017.00077

Morabito, 2004, J Bone Miner Res

Angelopoulos, 2006, Osteoporos Int

Chatterjee, 2012, Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome, Br J Haematol, 159, 462, 10.1111/bjh.12048

De Sanctis, 1996, Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine, Eur J Pediatr, 155, 368, 10.1007/BF01955263

Poggi, 2016, Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years, Ann Hematol, 95, 757, 10.1007/s00277-016-2633-y

Casale, 2014, Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major, Am J Hematol, 89, 1102, 10.1002/ajh.23844

Wong, 2016, Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria, Bone, 85, 55, 10.1016/j.bone.2016.01.011

Efthimia, 2013, Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience, Ann Hematol, 92, 263, 10.1007/s00277-012-1558-3

Saki, 2015, Molecular aspects of bone resorption in β-thalassemia major, Cell J, 17, 193

Wong, 2016, Bone disease in thalassemia: a molecular and clinical overview, Endocr Rev, 37, 320, 10.1210/er.2015-1105

Soliman, 2013, Vitamin D status in thalassemia major: an update, Mediterr J Hematol Infect Dis, 5, e2013057, 10.4084/mjhid.2013.057

Mirza, 2015, Management of endocrine disease: secondary osteoporosis: pathophysiology and management, Eur J Endocrinol, 173, R131, 10.1530/EJE-15-0118

Skordis, 2011, The multifactorial origin of growth failure in thalassaemia, Pediatr Endocrinol Rev, 8, 271

Scacchi, 2016, Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins, Endocrine, 53, 551, 10.1007/s12020-016-0865-1

Mangia, 2017, Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection, Aliment Pharmacol Ther, 46, 424, 10.1111/apt.14197

Quinn, 2011, Renal dysfunction in patients with thalassaemia, Br J Haematol, 153, 111, 10.1111/j.1365-2141.2010.08477.x

Couchman, 2017, Analytical considerations for the biochemical assessment of vitamin D status, Ther Adv Musculoskelet Dis, 9, 97, 10.1177/1759720X17692500

Golriz, 2017, Modern American scurvy: experience with vitamin C deficiency at a large children’s hospital, Pediatr Radiol, 47, 214, 10.1007/s00247-016-3726-4

Aghajanian, 2015, J Bone Miner Res

Ozdemir, 2013, The efficacy of vitamin K2 and calcitriol combination on thalassemic osteopathy, J Pediatr Hematol Oncol, 35, 623, 10.1097/MPH.0000000000000040

Ozturk, 2017, J Trace Elem Med Biol

Swe, 2013, Zinc supplements for treating thalassaemia and sickle cell disease, Cochrane Database Syst Rev, CD009415

Mikula, 2017, Osteoporos Int

Einy, 2016, Orthodontic consideration in patients with beta-thalassemia major: case report and literature review, J Clin Pediatr Dent, 40, 241, 10.17796/1053-4628-40.3.241

Cappellini, 2014

Giusti, 2016, Management of beta-thalassemia-associated osteoporosis, Ann N Y Acad Sci, 1368, 73, 10.1111/nyas.13041

Lampropoulou-Adamidou, 2016, Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature, J Musculoskelet Neuronal Interact, 16, 75

Lal, 2016, Assessment and treatment of pain in thalassemia, Ann N Y Acad Sci, 1368, 65, 10.1111/nyas.13061

Trachtenberg, 2010, Pain as an emergent issue in thalassemia, Am J Hematol, 85, 367, 10.1002/ajh.21670

Angastiniotis, 2008, Thalassaemic bone disease: an overview, Pediatr Endocrinol Rev, 6, 73

Green, 2014, Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients, Br J Haematol, 166, 797, 10.1111/bjh.12903

Vogiatzi, 2009, J Bone Miner Res

Desigan, 2006, Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs, Skeletal Radiol, 35, 95, 10.1007/s00256-005-0020-1

Oliveros, 2013, Pain over time and its effects on life in thalassemia, Am J Hematol, 88, 939, 10.1002/ajh.23565

Tanner, 2017, Case 243: extramedullary hematopoiesis in an adrenal myelolipoma, Radiology, 284, 292, 10.1148/radiol.2017142993

Noureldine, Rheumatology

Thông tin
Thông tin xuất bản

Hematology. American Society of Hematology. Education Program

Tập 2017 Số 1

272-277

Thông tin tác giả